Biofrontera (NASDAQ:BFRI) Announces Quarterly Earnings Results, Misses Expectations By $0.31 EPS

Biofrontera (NASDAQ:BFRI) released its earnings results on Friday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.31), FiscalAI reports. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. The business had revenue of $9.07 million during the quarter, compared to the consensus estimate of $8.50 million.

Here are the key takeaways from Biofrontera’s conference call:

• Positive Sentiment: FDA approval of Ameluz for superficial basal cell carcinoma gives Biofrontera a second U.S. indication and a non-surgical treatment option using lamps already in dermatology offices. The company expects a full commercial launch in the first quarter of 2027.
• Positive Sentiment: U.S. Customs cleared the redesigned RhodoLED XL-C from the ITC exclusion order, and Biofrontera says remediation has reduced the share of Ameluz sales affected by the order from about 25% to 10%. The company expects field remediation to be substantially complete by the end of the second quarter of 2027, though appeals remain pending.
• Positive Sentiment: Third-quarter revenue rose 29.8% year over year to $9.1 million, with Ameluz tube volume up about 23%; gross margin improved to 74.4% from 70.7%. Management cautioned that much of the volume growth reflected orders brought forward ahead of the ITC order taking effect.
• Positive Sentiment: Biofrontera submitted an application to expand Ameluz use to actinic keratosis on the extremities, neck, and trunk, with an FDA decision date of August 5, 2027. The company says approval could extend treatment to larger body areas using its existing lamps and sales force.
• Negative Sentiment: The company reported $3.2 million in cash at quarter-end and disclosed substantial doubt about its ability to continue as a going concern for at least 12 months. Its mitigation plans include revenue growth, a working credit line, a conditional $1 million divestiture milestone, and potential additional capital; management said these plans have not alleviated the doubt, and the company does not currently meet Nasdaq’s minimum stockholders’ equity requirement.

Biofrontera Trading Down 18.8%

Shares of BFRI stock traded down $0.17 on Friday, hitting $0.75. The company had a trading volume of 566,781 shares, compared to its average volume of 391,145. The firm has a market cap of $11.17 million, a P/E ratio of -1.67 and a beta of 0.88. The stock’s 50-day moving average is $1.04 and its two-hundred day moving average is $1.03. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.08 and a current ratio of 1.18. Biofrontera has a twelve month low of $0.55 and a twelve month high of $1.66.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Biofrontera in a research note on Tuesday, October 13th. Finally, Wall Street Zen lowered shares of Biofrontera from a “buy” rating to a “hold” rating in a report on Sunday, September 20th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Biofrontera currently has an average rating of “Hold”.

About Biofrontera

Biofrontera Inc. (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers. Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.